GSK to close U.S. consumer plant, eliminating 260 jobs

Production of the Emergen-C supplement will be moved to a facility in Puerto Rico after GlaxoSmithKline closes a plant in Carlisle, Pennsylvania, next near. (GlaxoSmithKline)

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The U.K. drugmaker, which now has a consumer products joint venture with Pfizer, says it has decided it is more cost efficient to consolidate production from the OTC plant to a facility in Guayama, Puerto Rico, said in an email confirming a report in the Patriot News. 

“Based on this decision, which impacts approximately 260 employees, production will be phased out of Carlisle by mid-2021, with a full exit by the end of 2021,” GSK said in statement.  


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

The GSK plant makes vitamin C supplement Emergen-C. The plant in Puerto Rico was contributed to the JV by Pfizer. A spokeswoman said jobs are expected to be added there with the production shift.

RELATED: GlaxoSmithKline's spinoff plan is here—and it may not be limited to consumer health

The two pharma giants completed a merger last year that combined their consumer products into an operation that will be spun off into a standalone business in the next several years. 

GSK, which owns the majority of the unit, is looking to gain £700 million in annual savings by 2022, with “improved operating performance” from then on. The JV generated sales of £9 billion ($11.7 billion) in 2019, up 2% on a pro forma basis. That included a 1% negative impact from divestments and the phasing out of low-margin contract manufacturing.

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.